Dr. Simeon George joined SR One in 2007 and leads its investment activities on the West Coast. Simeon is a director of Crispr Therapeutics (CRSP), eFFECTOR Therapeutics, Principia Biopharma, Progyny and Birdrock. Simeon previously was a director of Genocea (GNCA), HTG Molecular (HTGM) and Semprus Biosciences (acquired by Teleflex). Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch. Simeon received his M.D. from the University of Pennsylvania School of Medicine, his MBA (Mayer Scholar) from the University of Pennsylvania Wharton School of Business and his B.A. in neuroscience from the Johns Hopkins University, where he graduated Phi Beta Kappa.